Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.35 USD | -8.39% | -15.62% | -31.32% |
Mar. 28 | Health Care Rises as Upward Momentum Builds -- Health Care Roundup | DJ |
Mar. 27 | Health Care Jumps as Upward Momentum Builds -- Health Care Roundup | DJ |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.32% | 142M | C+ | ||
+9.30% | 46.03B | B | ||
+52.73% | 44.55B | A | ||
+7.15% | 40.8B | B- | ||
-5.11% | 28.25B | C | ||
+18.68% | 27.71B | B- | ||
-21.92% | 18.82B | B | ||
+14.62% | 13.91B | C+ | ||
+31.85% | 12.43B | C+ | ||
-8.77% | 11.06B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Syros Pharmaceuticals, Inc. - Nasdaq
- Ratings Syros Pharmaceuticals, Inc.